Importantly, 10c (80 mg/kg) demonstrated moderate tumour suppressing effects in a mouse model of B16-F10 melanoma tumour with a TGI of 32.9%, comparable to that (TGI = 31.3%) of tubastatin A. Noticeably, the combination of 10c with NP19 (a small molecule PD-L1 inhibitor reported by us before) decreased the tumour burden substantially (TGI% = 60.1%) when compared to monotherapy groups. The gene discussed is CD274; the disease is neoplasm.